Daily Stock List
CareView Communications, Inc. (CRVW)
Stock Stars, MonsterStocksPick, FeedBlitz, Real Pennies, PennyTrader Publisher, Wall Street Resources, BabyBulls, Tiny Gems, and MissionIR reported previously on CareView Communications, Inc. (CRVW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
CareView Communications, Inc. is an information technology provider to the healthcare industry. It provides the next generation of patient care through its innovative data and patient monitoring system. This system connects patients, families and healthcare professionals (the CareView System®). CareView Communications is based in Lewisville, Texas. The Company’s shares trade on the OTC Bulletin Board.
CareView Communications’ objective is to be the top provider of products and on-demand application services for the healthcare industry. This is through specializing in bedside video monitoring, archiving and patient care documentation systems and patient entertainment services. Presently, CareView Communications products are installed in greater than 8,200 patient beds and are helping to improve care in more than 90 acute care facilities.
CareView Communications’ proprietary, high-speed data network system may be deployed throughout a healthcare facility to provide the facility with recurring revenue and infrastructure for future applications. The Company’s dedication is to working with all types of hospitals, nursing homes, adult living centers, as well as selected outpatient care facilities domestically and around the world.
The Company’s CareView System can help a hospital lessen sitter costs, decrease patient falls and injuries, manage patient flow, improve internal communications, and consolidate vendors. The CareView System allows for close observation of high-risk patients from multiple locations. This is to lessen sitter costs and manage staffing resources more efficiently. In addition, the CareView Connect® mobile application provides patient monitoring and essential communication tools from an existing Wi-Fi Android or iOS device.
In October 2015, CareView Communications announced that it drew down $20 million under its existing credit agreement with PDL BioPharma, Inc. and, in connection with the drawdown, entered into an amendment to the credit agreement. PDL manages a portfolio of patents and royalty assets and looks to provide non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies.
CareView Communications, Inc. (CRVW), closed Monday's trading session at $0.30, up 20.00%, on 77,550 volume with 17 trades. The average volume for the last 60 days is 72,975 and the stock's 52-week low/high is $0.205/$0.565.
GroGenesis, Inc. (GROG)
Terry’s Tips, Flagler Financial Group, StreetAuthority Financial, Trade of the Week, ProfitableTrading, Dividend Opportunities, SECFilings.com News, Insider Wealth Alert, and Investors Alley reported earlier on GroGenesis, Inc. (GROG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
GroGenesis, Inc.’s goal is to become a top producer of natural plant growth health technologies. The Company is rights holder, developer, and manufacturer of creative plant health enhancement products branded as AgraBurst and AgraBlast. GroGenesis is working to position itself in the fast expanding fertilizer, surfactant, fungicide, and plant growth enhancement space as a business distinguished for safe, productive technology and proprietary solutions. GroGenesis is based in Springville, Tennessee.
Its AgraBurst is a plant growth technology blended from processed extracts of natural plant materials, which directly improves the positive effects of commercial fertilizers and available nutrients. AgraBurst™ is its flagship product. It works at the cellular level to hasten the absorption of vital nutrients, chemicals, and water by way of molecular penetration of the plant’s leaf.
In addition, GroGenesis offers "AgraBlast". This is an eco-friendly, non-toxic alternative to synthetic fungicides. When used in combination (as directed), GroGenesis provides an innovative solution for the control of plant pathogenic fungi and for plant remediation and stimulation of yields. AgraBlast is a broad-spectrum algaecide, fungicide, bactericide, and general sanitation product for the control and prevention of horticultural diseases and pathogens in pre-harvest, post-harvest and storage of field-grown crops.
Furthermore, the Company is working to become a world leading provider of eco-friendly, non-toxic, plant growth and health enhancers. Moreover, GroGenesis is working to enable farmers and agribusinesses to substantially boost crop yields around the world while lessening the effects of over-fertilization.
GroGenesis provides a technology that alleviates many of the challenges of fertilizer application through introducing a surfactant to plant foliage as a unique delivery system to speed up absorption of water and nutrients on-leaf, while at the same time increasing root uptake.
GroGenesis has resolved to refine the market segmentation and commercial roll out potential for its first two products: AgraBurst and AgraBlast. The Company’s Management concluded, based on internal studies, to realize increased market awareness in the nascent biostimulant sector. This is a recent and growing industry classification that shows considerable promise as an agricultural interconnection of new technological advancements and commercial adoption.
This past November, GroGenesis announced the appointment of Mr. David Colburn to its Board of Directors. Mr. Colburn has more than 30 years of operating and executive level experience in public and private enterprises serving as President/CEO of six companies and COO of two companies. He has an extensive operating background in automotive, industrial, technology and manufacturing.
GroGenesis, Inc. (GROG), closed Monday's trading session at $0.09, up 12.50%, on 6,889 volume with 3 trades. The average volume for the last 60 days is 17,720 and the stock's 52-week low/high is $0.05/$1.06.
Heritage Global, Inc. (HGBL)
SmallCapVoice and TheMicrocapNews reported on Heritage Global, Inc. (HGBL), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Heritage Global, Inc. is a leader in asset liquidation transactions, valuations, as well as advisory services. It concentrates on identifying, valuing, acquiring, and monetizing underlying assets in 28 worldwide manufacturing and technology sectors. The Company’s operating companies are Heritage Equity Partners, Heritage Global Partners, Heritage Global Valuations, Heritage NLEX, and Heritage Zetabid Realty Services. Heritage Global is based in San Diego, California.
The Company’s objective is to conduct all of its business under its two principal platforms: Heritage Global Partners for auctions, valuations, acquisitions and dispositions of surplus assets and plant closures, and Heritage Equity Partners (HEP) for advisory services and disposition services of distressed and non-distressed continuing enterprise sales. Heritage Equity Partners (HEP), formerly “Equity Partners,” is based in Easton, MD. HEP provides boutique investment banking services for special situations.
Heritage Global specializes in acting as an adviser and acquiring or brokering turnkey manufacturing facilities, surplus industrial machinery and equipment, industrial inventories, accounts receivable portfolios and related intellectual property (IP), and entire business enterprises. It has completed hundreds of transactions since forming, acting as principal and advisor and member of different syndicates together with distressed and surplus asset industry leaders.
Heritage Global has launched Heritage Zetabid Realty Services (HZRS). This is its real estate auction platform and services division. HZRS complements and expands Heritage Global’s existing asset valuation, advisory, and auction capabilities through adding new service offerings and experienced industry professionals to effectively market and monetize clients’ commercial, industrial, and luxury/bank-owned residential real estate assets. Heritage Zetabid Realty Services is a strategic alliance between Heritage Global and Zetabid, a leading provider of real estate marketing services.
Heritage Global has launched Heritage Global Capital (HGC). This is its fixed asset financing services division. HGC complements and expands Heritage Global’s existing asset valuation, advisory, and auction capabilities by adding new service offerings centering on providing term loans and leases secured by equipment and real estate.
Last week, Heritage Zetabid Realty & Auction Services, a division of Heritage Global, announced the sale at public auction of the Vineland Kosher Poultry Plant in Vineland, New Jersey. The 30-acre site features more than 55,000 square feet of industrial space. It has a fully-functional poultry processing plant and all machinery intact. The site is USDA approved and holds major waste water and supply water permits. The online auction is scheduled to occur March 1 through March 10, 2016. It will be conducted at www.zetabid.com.
Heritage Global, Inc. (HGBL), closed Monday's trading session at $0.216123, up 27.13%, on 7,420 volume with 9 trades. The average volume for the last 60 days is 44,472 and the stock's 52-week low/high is $0.05/$0.51.
CTD Holdings, Inc. (CTDH)
Wall Street Resources reported previously on CTD Holdings, Inc. (CTDH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
CTD Holdings, Inc. is a biotechnology company developing cyclodextrin-based products for the treatment of disease. This includes Trappsol® Cyclo™. The Company’s other divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies engaged in the research, pharmaceutical, medical device, cosmetics, and nutrition markets. CTD Holdings is headquartered in Alachua, Florida.
The Company’s Trappsol® Cyclo™ is an orphan drug designated product. It is for the treatment of Niemann-Pick Type C (NPC), a rare and frequently fatal genetic disease in young children that also results in major health impairment for affected adults. Additional indications for the active ingredient in Trappsol® Cyclo™ are also in development. This includes peripheral artery disease, diabetic nephropathy, and acute viral infections.
In addition, CTD Holdings’ other divisions operate the world's only cGMP pulse drying facility for the production of UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. Moreover, they supply cyclodextrins to biotechnology and life science researchers around the world from the world's largest catalog of cyclodextrins.
This past December, CTD Holdings announced that it received positive responses from a major United Kingdom healthcare regulator to the clinical trial design for its Trappsol® Cyclo™ drug used to treat Niemann-Pick Type C (NPC). The Medicines and Healthcare Products Regulatory Agency (MHRA) provided positive responses to CTD Holdings’ major clinical study design elements. This includes safety and toxicity, patient inclusion and exclusion criteria, and biochemical analysis and clinical outcomes.
The MHRA advice holds that CTD Holdings has sufficient pre-clinical data to support its clinical trial. The Company will prepare a formal clinical trial application for the MHRA at which time it may receive additional feedback. CTD Holdings will choose sites in the United Kingdom for its Phase II trial. The Company expects to start enrolling United Kingdom patients in early 2016.
CTD Holdings, Inc. (CTDH), closed Monday's trading session at $0.28, up 12.00%, on 41,630 volume with 21 trades. The average volume for the last 60 days is 11,392 and the stock's 52-week low/high is $0.25/$0.80.
Precision Optics Corp., Inc. (PEYE)
PennyStockScholar, OTCtipReporter, SmallCapInvestorDaily, Pumps and Dumps, Michael Stone, InvestorTrendz, Club Penny Stocks Network, Growing Stocks Reports, Research Driven Investor, and Bull Trends reported on Precision Optics Corp., Inc. (PEYE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Utilizing proprietary optical technologies, Precision Optics Corp., Inc. is a leading developer and manufacturer of advanced optical instruments. It designs and produces next generation medical instruments, Microprecision™ micro-optics with characteristic dimensions under 1 millimeter, as well as other advanced optical systems for a wide spectrum of customers. Precision Optics has its corporate office in Gardner, Massachusetts.
The Company’s expertise includes the design, development, and manufacturing of optical and mechanical-optical components, sub-assemblies, and systems. These include lenses, prisms, thin film coatings, optical assemblies, sinuscopes, arthroscopes, laparoscopes, stereo-endoscopes, beamsplitters, endocouplers, camera adapters and fiber optic assemblies.
Precision Optics developed the Cidex™ soakable endocoupler in 1983; developed the first commercially available stereoendoscope; and patented premier durability and easy to repair sinuscopes and arthroscopes. The Company has expertise in providing lenses to sizes as small as 0.2mm in diameter utilizing its proprietary Microprecision™ technology with the quality of ground lenses approaching the cost of gradient index (GRIN) lenses.
Last week, Precision Optics announced operating results on an unaudited basis for the Company’s Q2 and six months ended December 31, 2015, of fiscal year 2016. Q2 highlights include revenues of $955,000, representing an 11.2 percent sequential increase over Q1 of fiscal 2016, and a 2.2 percent decline over Q2 of fiscal 2015.
The Company had a gross margin of 22.7 percent. This represents an improvement, versus 15.4 percent in Q1 of fiscal 2016, and versus 16.6 percent in Q2 of fiscal 2015. Precision Optics had an ongoing increase in engineering/design projects, and associated revenue, using its Microprecision™ optics for reusable and single-use medical devices.
Precision Optics’ Chief Executive Officer, Mr. Joseph Forkey, said, “This last quarter marks another step in Precision Optics’ progress towards profitable operations built upon new product technologies and an expanding customer base. While total revenue was only slightly higher during the six months ended December 2015 compared to the previous year, revenue from new product activities versus traditional products increased 13 percent and is now at 71 percent of total sales.”
Precision Optics Corp., Inc. (PEYE), closed Monday's trading session at $0.60, up 30.43%, on 2,853 volume with 5 trades. The average volume for the last 60 days is 20,540 and the stock's 52-week low/high is $0.35/$1.02.
Immune Therapeutics, Inc. (IMUN)
The QualityStocks Daily Newsletter would like to spotlight Immune Therapeutics, Inc. (IMUN). Today, Immune Therapeutics, Inc. closed trading at $0.177, up 0.57%, on 52,915 volume with 12 trades. The stock’s average daily volume over the past 60 days is 147,846, and its 52-week low/high is $0.045/$0.36.
Immune Therapeutics, Inc. (IMUN) is a biotechnology company applying its patented immunotherapy to combat chronic, life-threatening diseases that affect persons around the world. Building on the power of the body's natural immune system, the company's pipeline of products and immunotherapy technologies are designed to enhance treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases.
Immune Therapeutics' most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and its low dose naltrexone product (LDN), internationally known as Lodonal™, both of which have been shown to stimulate immune systems even in patients with advanced cancer.
Additionally, Immune Therapeutics is pursuing additional investigations for MENK and LDN as viable treatments for autoimmune conditions such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.
Immune Therapeutics and partners AHAR Pharma and GB Pharma Holdings recently completed a bridging trial to determine the safety and efficacy of LDN in patients with HIV, and have submitted data in connection with the filing of its New Drug Application for LDN with The National Agency for Food and Drug Administration and Control, (NAFDAC) of Nigeria. Disclaimer
Immune Therapeutics, Inc. Company Blog
Immune Therapeutics, Inc. News:
Immune Therapeutics, Inc to Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016
SeeThruEquity Initiates Coverage on Immune Therapeutics, Inc. with a Price Target of $0.61
Immune Therapeutics, Inc. Announced the Completion of the Bridging Trial
Oakridge Global Energy Solutions, Inc. (OGES)
The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.65, up 4.84%, on 96,398 volme with 108 trades. The stock’s average daily volume over the past 60 days is 18,897, and its 52-week low/high is $0.20/$2.40.
Oakridge Global Energy Solutions, Inc., reported today on how, as of January 25 through January 28, 2016 that Man-Portable Tactical Autonomous Systems company MARTAC held field trials for a major defense contractor utilizing several different sizes of their high speed maritime vessels in the Indian River in Palm Bay, Florida, powered by custom-tailored, high performance, Oakridge batteries which were designed and produced by Oakridge specifically for Martac’s application. These trials were a major success and left all participants exceptionally pleased with the results.
Oakridge Global Energy Solutions, Inc. (OGES) is an integrated energy storage solutions company focused on the design, development and manufacture of high-quality cells, batteries and power systems. The company's innovative 'Made in the U.S.A.' product line includes multiple lithium-ion technologies and form factors that are optimized to address three high-demand target markets – including stationary and grid storage; motive applications, such as electric and hybrid electric fleet vehicles; and specialty applications, such as military, aerospace, marine, medical and telecom backup.
Through a recent restructuring of its operations, Oakridge strategically positioned itself to expand its market reach moving forward. The company currently owns and operates two manufacturing facilities in Melbourne, Florida, which play an instrumental role in its efforts to meet the growing demand for its cutting-edge large format Pro Series golf car batteries and its small format Patriot Series RC batteries. These operations also allow Oakridge to bring stable employment opportunities back to the U.S., effectively highlighting its tireless commitment to the revitalization of the country's manufacturing industry.
The company also maintains a presence on the international stage through its recently formed subsidiary, Oakridge Global Energy Solutions Limited, Hong Kong. This subsidiary, which is expected to serve as the foundation for Oakridge's sales efforts throughout the Asia-Pacific region, was created primarily to address the tremendous international demand for its revolutionary stored energy solutions. The company also maintains a substantial interest in Leclanche S.A., a Swiss developer and manufacturer of large-sized lithium-ion batteries that was originally founded in 1909.
Oakridge has indicated plans to expand its presence in a collection of markets throughout Europe and Asia as it continues to build upon its established product development and manufacturing infrastructure. The company will lean on the expertise of its proven management team – which includes well over a century of combined industry experience – as it looks to increase its share of the $12 billion domestic battery manufacturing industry. Disclaimer
Oakridge Global Energy Solutions, Inc. Company Blog
Oakridge Global Energy Solutions, Inc. News:
Oakridge Powered MARTAC Demonstration Huge Success
Oakridge Announces New Corporate Image, Branding and Media Communications Tools as it Enters Full-Scale Production for 2016
Oakridge Providing Batteries for Unmanned Maritime Vessels
Torchlight Energy Resources, Inc. (TRCH)
The QualityStocks Daily Newsletter would like to spotlight Torchlight Energy Resources, Inc. (NASDAQ:TRCH). Today, Torchlight Energy Resources, Inc. closed trading at $0.5577, up 7.25%, on 63,307 volume with 209 trades. The stock’s average daily volume over the past 60 days is 115,096, and its 52-week low/high is $0.2201/$2.44.
Torchlight Energy Resources, Inc. (NASDAQ:TRCH) is a high growth oil and gas Exploration and Production (E&P) company primarily focused on the acquisition and development of highly profitable domestic oil fields. Leveraging a diverse portfolio, carefully selected interests, and a strong management team are pillars of Torchlight's broader success strategy.
The company maintains a diversified energy portfolio by holding interests in numerous projects in multiple established plays, and currently holds interests in Texas, Oklahoma and Kansas, where its targets are established plays such as the Wolf Penn, Eagle Ford Shale, Mississippi Limestone and Hunton Limestone trends.
Torchlight is currently moving forward on the next phase of drilling on three new wells in its Orogrande Project in West Texas, where the company owns a 47.5% working interest on 168,000 acres alongside Founders Oil and Gas, LLC. Torchlight drilled the Rich A-11 well (6,091 feet) on the Orogrande Project in March last year and subsequently executed a $50 million JV farm-out agreement with Midland, Texas-based Founders Oil and Gas, who initiated frac work on the well in November.
The Marcelina Creek Project in South Texas, with its prime access to the Austin Chalk, Buda, and Eagle Ford formations, is surrounded on all four sides by leading Eagle Ford producers. Torchlight's Johnson #4 well was recently re-entered and drilled laterally to approximately 2500 feet in the Austin Chalk Formation. With more than 20 additional drilling locations on its Marcelina Creek Asset, the project has the potential to positively impact cash flows and production sustainability.
Torchlight's executive team and board of directors are led by CEO John Brda and COO Willard McAndrew III. Combined they have over 50 years of experience in the oil and gas industry as executives, investors and consultants to the industry. Their knowledge base includes all aspects of the business including: operations, mid stream, capital formation, purchase and sale of assets, re-entries, investor relations and oil and gas consulting for public and private companies. Disclaimer
Torchlight Energy Resources, Inc. Company Blog
Torchlight Energy Resources, Inc. News:
Torchlight Energy Provides Update on the Orogrande Project
Year-End Review 2015: Torchlight Energy (NASDAQ: TRCH) by StockNewsNow
Torchlight Energy Announces Success on Its Johnson #4 Re-Entry
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $2.65, up 6.85%, on 1,400 volume with 9 trades. The stock’s average daily volume over the past 60 days is 11,644, and its 52-week low/high is $1.25/$11.625.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease
International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products
Lingo Media Corp. (LMDCF)
The QualityStocks Daily Newsletter would like to spotlight Lingo Media Corp. (LMDCF). Today, Lingo Media Corp. closed trading at $0.5437, even for the day. The stock’s average daily volume over the past 60 days is 6,097, and its 52-week low/high is $0.0862/$0.6745.
Lingo Media Corp. (LMDCF) (LM.V) is an EdTech company that's changing the way the world learns English through an innovative combination of proven educational techniques and accessible technology. The company provides both online and print-based solutions through its two distinct business units: ELL Technologies and Lingo Learning. Through ELL Technologies, Lingo has made considerable progress in English-learning markets throughout Latin America. Through print-based publisher Lingo Learning, the company has built a significant presence in the Chinese education market, which includes more than 300 million students.
The company's groundbreaking English programs are developed and marketed for students at every stage of development – from the classroom to the boardroom. This versatility has allowed Lingo to secure contracts and build relationships with clients in a variety of markets around the globe. In Mexico, a subsidiary of the company has partnered with a recognized university that allows it to offer its courses along with certification. In Peru, the company's subsidiary provides its groundbreaking Scholar program to a branch of the country's armed forces.
Through ELL Technologies, Lingo also markets electronic learning solutions that are suitable for pre-readers. Lingo's Kids program – which features cross-platform, multi-browser compatibility – requires no prior knowledge of the English language, allowing the company to address the entire student life cycle in blended learning environments, traditional classroom settings and the home with one cutting-edge solution. The Kids program addresses the critically underserved pre-school market, which includes roughly 181.4 million children across Asia and 30.1 million throughout Latin America and the Caribbean, according to UNESCO.
Although Lingo has traditionally leaned on its print-based offerings as a primary source of revenue, the company's recent efforts to shift into the thriving eLearning market have highlighted the immense potential of a more heavily digital approach. In the second quarter of 2015, Lingo recorded more revenue from digital products than print-based solutions for the first time in its history. With the global eLearning market set to reach $107 billion in 2015, according to a report by Global Industry Analysts, the company's performance and growing foothold in some of the world's most rapidly expanding markets place it in a favorable position. Disclaimer
Lingo Media Corp. Company Blog
Lingo Media Corp. News:
Lingo Media to Present at the World Outlook Financial Conference 2016 on January 29th & 30th
Lingo Media Corp. (LMDCF) (LM.V) Continues to Generate Strong Profits with Q3 Net Income of $631,730
Lingo Media to Present at the LD Micro Main Event
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Agora Holdings, Inc. (AGHI) CEO Featured in Exclusive QualityStocks Interview
- Alternet Systems (ALYI) Announces Caprock Research Report with Near Term Price Target of $0.05 and 'Accumulate' Recommendation
- Avant Diagnostics, Inc. (AVDX) To Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016
- Cherubim Interests, Inc. (CHIT) Signs MOU to Acquire Revenue-Producing Company
- Dominovas Energy Corp. (DNRG) Agrees to Acquire Grupo Trebol in Guatemala City, Guatemala
- FlexWeek, Inc. (FXWK) Announces Engagement of QualityStocks Corporate Communications Suite
- Giggles N' Hugs, Inc. (GIGL) CEO Discusses 2016 Growth Strategies in Second QualityStocks Interview
- GTX Corp. (GTXO) to Present at 2nd Annual Innovations Investor Conference and Announces Date of Shareholder Meeting
- Immune Therapeutics, Inc. (IMUN) to Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016
- International Stem Cell Corp. (ISCO) Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
- Lingo Media Corp. (LMDCF) to Present at the World Outlook Financial Conference 2016 on January 29th & 30th
- Moxian, Inc. (MOXC) Enters Into Exclusive Agreement and Development Partnership With Xinhua Media Affiliate
- Nutra Pharma Corp. (NPHC) to Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016
- Oakridge Global Energy Solutions, Inc. (OGES) Powered MARTAC Demonstration Huge Success
- OurPet's Company (OPCO) Expects New Product Line to Make Big Splash at Global Pet Expo
- Star Mountain Resources Inc. (SMRS) Receives Industry Guide 7 Mineral Reserves Report on Balmat Mine
- Torchlight Energy Resources, Inc. (TRCH) Provides Update on the Orogrande Project
- View Systems, Inc. (VSYM) to Acquire Y.M. Advantage, Inc.